DeepIntent, a demand-side platform that helps healthcare and pharma brands including AstraZeneca, Bayer, Gilead, and Johnson & Johnson buy ad space, announced Tuesday that it’s secured a $637 million investment from private equity firm Vitruvian Partners.
Vitruvian acquires a majority share in the company with this investment. DeepIntent’s board of directors will be “reconstituted to include a select group of industry leaders and domain experts,” with the company continuing to operate independently under current chief executive and founder Chris Paquette, according to a joint statement shared Tuesday.
New board members have not been announced.
DeepIntent said it planned to use the new capital to build out and integrate generative AI tools within its tech stack.
UNLOCK FULL ACCESS
Subscribe and get full access to the news, insights, and expertise that keep industry professionals ahead of the curve.
VIEW ALL SUBSCRIPTION OPTIONS
